Comparative Pharmacology
Head-to-head clinical analysis: ADALAT versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT versus TRIVARIS.
ADALAT vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Calcium Channel Blocker
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination